Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

11 sept. 2017 08h00 HE | Source: Atara Biotherapeutics, Inc.

Atara Biotherapeutics Receives Positive Health Canada Regulatory Feedback for ATA129

Health Canada New Drug Submission (NDS) planned based on Phase 1 and 2 clinical results and supported by available data from anticipated MATCH and ALLELE Phase 3 studies, which are expected to be...
05 sept. 2017 08h00 HE | Source: Atara Biotherapeutics, Inc.

Atara Biotherapeutics Receives FDA Orphan Drug Designation for ATA230

SOUTH SAN FRANCISCO, Calif., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading "off-the-shelf" T-cell immunotherapy company developing novel treatments for...
31 août 2017 16h15 HE | Source: Atara Biotherapeutics, Inc.

Atara Biotherapeutics to Participate in Three Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading "off-the-shelf" T-cell immunotherapy company developing novel treatments for...
22 août 2017 16h34 HE | Source: Atara Biotherapeutics, Inc.

Atara Biotherapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Aug. 22, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading "off-the-shelf" T-cell immunotherapy company developing novel treatments for...
22 août 2017 08h00 HE | Source: Atara Biotherapeutics, Inc.

Atara Biotherapeutics Expands Leadership Team with the Appointment of Dr. Kanya Rajangam as Senior Vice President and Chief Medical Officer

SOUTH SAN FRANCISCO, Calif., Aug. 22, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading "off-the-shelf" T-cell immunotherapy company developing novel treatments for...
07 août 2017 16h05 HE | Source: Atara Biotherapeutics, Inc.

Atara Biotherapeutics Announces Second Quarter 2017 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading "off-the-shelf" T-cell immunotherapy company developing novel treatments for...
02 août 2017 08h00 HE | Source: Atara Biotherapeutics, Inc.

Atara Biotherapeutics to Present at the Canaccord Genuity 37th Annual Growth Conference

SOUTH SAN FRANCISCO, Calif., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading "off-the-shelf" T-cell immunotherapy company developing novel treatments for...
31 juil. 2017 08h09 HE | Source: Atara Biotherapeutics, Inc.

Atara Biotherapeutics Announces Two Presentations at MSParis2017, Including Updated, Interim Results from a Phase 1 Study of Autologous ATA188 in Patients with Progressive Multiple Sclerosis (MS)

New results characterizing the molecular signature of Epstein-Barr Virus (EBV) in MS brain lesions will also be presented Presentations to take place during the upcoming MSParis2017 Congress, the 7th...
24 mai 2017 08h00 HE | Source: Atara Biotherapeutics, Inc.

Atara Biotherapeutics to Present at Three Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., May 24, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that the Company will present at three upcoming investor conferences in June: ...
10 mai 2017 17h00 HE | Source: Atara Biotherapeutics, Inc.

Atara Biotherapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., May 10, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that the compensation committee of Atara’s board of directors, approved a...

Page précédente